Speciality Medicines IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Day-wise Subscription (times subscribed)
Financial Analysis
| Metric | 2024 | 2025 | Oct 2025 |
|---|---|---|---|
| Revenue | 27.66 | 58.54 | 36.93 |
| Expense | 23.10 | 49.85 | 30.80 |
| Profit (PAT) | 2.93 | 8.61 | 6.06 |
| Total Assets | 22.68 | 39.98 | 45.57 |
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Remus Pharmaceuticals Limited | 65.21 | 12.25 | 15 |
| Trident Lifeline Limited | 10.22 | 27.59 | 18 |
| Mono Pharmacare Limited | 1.75 | 13.87 | 10 |
Promoters: Parth B Goyani and Goyani Sumit Babubhai
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 64,35,796 | 59.28% |
| Promoter Holding Post Issue | 87,85,796 | 43.44% |
Strengths & Risks
- Strong institutional (QIB) demand — 96.2x.
- Revenue grew 112% in the latest reported year.
- Solid profit margin — 14.7%.
- Strong return on equity — 38%.
- Low leverage — debt/equity of 0.17.
- Promoter stake drops to 43% after the issue.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
One of the leading companies,” Speciality Medicines” was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases. Moreover, the company operates in two ways: (a) contract manufacturing of finished formulations for international markets, and (b) marketing and distribution of sourced specialty pharmaceutical products. Further, the company has around 7 registered products overseas, and 54 products are in the registration process across 5 countries.
Speciality Medicines Ltd., 913, One World West, S. No. 396, FP 119,, Village- Vejalpur, Ahmadabad City,, Ahmedabad, Gujarat, India,, Ahmedabad, Gujarat, 380051
| Purpose | Amount (Cr) |
|---|---|
| Setting up of the Research and Development (R&D) Centre | 13.31 |
| Product registration in the international markets | 2.89 |
| Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company | 1.75 |
| To Meet Working Capital Requirements | 12.00 |
| General Corporate Purpose | - |
Resources & Documents
Speciality Medicines has set a price band of Rs 117–Rs 124 per share for an issue size of Rs 29 crore. The stock listed flat against its issue price.
One of the leading companies,” Speciality Medicines” was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases. Moreover, the company operates in two ways: (a) contract manufacturing of finished formulations for international markets, and (b) marketing and distribution of sourced specialty pharmaceutical products.
The issue is promoted by Parth B Goyani and Goyani Sumit Babubhai with Unicon Capital Services Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Setting up of the Research and Development (R&D) Centre (Rs 13 crore) and Product registration in the international markets (Rs 3 crore).
On fundamentals, the company is posting revenue growth of 111.6%, a profit margin of 14.7%, return on equity of 37.9% in its most recent reported period. Listed peers in this segment include Trident Lifeline Limited (P/E 27.59x, market cap Rs 18 crore) and Remus Pharmaceuticals Limited (P/E 12.25x, market cap Rs 15 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Speciality Medicines IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed.
See the full Speciality Medicines GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!